Trial Profile
A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Jaktinib (Primary)
- Indications Autoimmune disorders; Cancer; Myelofibrosis
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 28 Feb 2019 Status changed from recruiting to completed.
- 02 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 02 Aug 2018 Planned primary completion date changed from 1 Nov 2017 to 30 Aug 2018.